THE IMPACT OF COVID-19 PANDEMIC ON THE CONSUMPTION OF ANTIDIABETIC DRUGS IN SERBIA: A JOINPOINT TREND ANALYSIS

Jelena Filimonovic
Jelena Filimonovic

Department of Epidemiology, Faculty of Medicine, University of Pristina temporarily seated in Kosovska Mitrovica , Kosovska Mitrovica , Serbia

Public Heath Institute of Kosovska Mitrovica, Public Heath Institute of Kosovska Mitrovica , Kosovska Mitrovica , Serbia

Published: 17.02.2025.

Volume 52, Issue 4 (2023)

pp. 4-9;

https://doi.org/10.70949/pramed202504000F

Abstract

Background: People with diabetes more often experienced severe clinical forms of COVID-19. However, it has been hypothesized that certain antidiabetic drugs may be associated with better outcomes in COVID-19 patients. The aim of this study was to analyze whether the COVID-19 pandemic influenced the change in consumption of antidiabetic drugs in Serbia.

Methods: This descriptive analysis was carried out using publicly accessible data obtained from the official website of the Medicines and Medical Devices Agency of Serbia during the period 2006-2022. The joinpoint regression analysis was applied to investigate the dynamics of antidiabetic drugs utilization over time.

Results: In the Republic of Serbia, this study analyzed the use of 28 antidiabetic drugs between 2006 and 2022.The results showed that at the beginning of the COVID-19 pandemic, there was an increase in consumption of dulaglutide (starting from 2020) and a decrease in consumption of insulin detemir (starting from 2019), insulin lispro (combined) and insulin lispro (fast-acting) (starting from 2020).

Conclusion: Our study revealed significant changes in the usage of certain antidiabetic drugs, such as increased consumption of dulaglutide and decreased use of various insulin types. These changes reflect the evolving strategies in diabetes treatment to better support patients during this global health crisis.

Key words: antidiabetic drugs, impact of Covid-19, consumption, Serbia

Keywords

References

1.
with COVID-19. Lancet Diabetes Endocrinol. 2020;8(6):546–50.
2.
Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD. Diabetes Care. 2022;45(11):2753–86.
3.
Davies MJ, Aroda VR, Collins BS, Gabbay RA. Management of hyperglycemia in type 2 diabetes. 2022;
4.
2023;46(Suppl 1).
5.
Association AD. Pharmacologic approaches to Glycemic Treatment: standards of Medical Care in Diabetes-2023. Diabetes Care.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by